Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) had its target price upped by equities researchers at The Goldman Sachs Group from $36.00 to $41.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. The Goldman Sachs Group's target price suggests a potential downside of 7.84% from the company's current price.
Several other equities research analysts also recently commented on TARS. William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $54.20.
Get Our Latest Analysis on TARS
Tarsus Pharmaceuticals Stock Down 4.6 %
NASDAQ TARS traded down $2.16 on Friday, hitting $44.49. 999,902 shares of the company were exchanged, compared to its average volume of 727,913. Tarsus Pharmaceuticals has a 12 month low of $15.60 and a 12 month high of $52.99. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.69 billion, a PE ratio of -11.60 and a beta of 1.00. The stock has a fifty day moving average of $37.55 and a 200-day moving average of $32.43.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC bought a new position in Tarsus Pharmaceuticals during the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board purchased a new position in Tarsus Pharmaceuticals during the second quarter worth about $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock worth $166,000 after purchasing an additional 1,530 shares in the last quarter. FMR LLC grew its position in Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares in the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $202,000. Institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
